Evotec SE (NASDAQ:EVO - Get Free Report)'s share price gapped down before the market opened on Friday . The stock had previously closed at $4.70, but opened at $4.57. Evotec shares last traded at $4.57, with a volume of 5,992 shares.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a "buy" rating and set a $8.00 price target on shares of Evotec in a research note on Thursday, November 7th.
Get Our Latest Research Report on EVO
Evotec Trading Down 3.0 %
The business has a fifty day simple moving average of $4.43 and a two-hundred day simple moving average of $4.03. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 0.43.
Institutional Trading of Evotec
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Clear Harbor Asset Management LLC bought a new position in Evotec in the 3rd quarter valued at approximately $104,000. Mediolanum International Funds Ltd bought a new position in Evotec in the 3rd quarter valued at approximately $512,000. DCF Advisers LLC lifted its position in Evotec by 5.9% in the 4th quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock valued at $956,000 after acquiring an additional 12,816 shares in the last quarter. Finally, Wellington Management Group LLP lifted its position in Evotec by 29.7% in the 3rd quarter. Wellington Management Group LLP now owns 2,634,434 shares of the company's stock valued at $9,616,000 after acquiring an additional 602,858 shares in the last quarter. Hedge funds and other institutional investors own 5.81% of the company's stock.
Evotec Company Profile
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Featured Articles
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
